鲁索替尼乳膏能有效治病吗？

Introduction: Ruxolitinib cream is a prescription medicine used for the topical treatment of a type of vitiligo called non-segmental vitiligo in adults and children 12 years and older. Ruxolitinib cream is not recommended for use with therapeutic biologics, other JAK inhibitors, or strong immunosuppressants such as azathioprine or cyclosporine.

Can the generic version of ruxolitinib cream also be effective in treating diseases?

The generic version of ruxolitinib cream can also be effective in treating diseases, such as the Bangladeshi Isida version and the Bangladesh Yaopin International version. The main ingredients, mechanism of action, and efficacy of the generic version of ruxolitinib cream are basically the same as those of the original drug. Therefore, when used correctly, generic drugs can also significantly relieve patients' symptoms. Generic ruxolitinib cream has shown significant efficacy in clinical trials. It can effectively reduce symptoms such as itching, rash and redness in patients with atopic dermatitis. In patients with vitiligo, generic drugs can also promote the recovery of skin pigment and improve the appearance of the skin.

Patients should pay close attention to body reactions when using generic drugs, and use them under the guidance of a doctor to understand the side effects, dosage, efficacy, etc. of the drug.

Efficacy of ruxolitinib cream

In two Phase 3 clinical trials of ruxolitinib cream, after 8 weeks of continuous use, 53.8% and 51.3% of patients met the primary endpoint of Investigator Global Assessment of Treatment Success (IGA-TS) 0-1 (clear or almost clear) and had at least a grade 2 improvement since the start of the trial. In comparison, only 7.6% of patients received placebo.

Among the patients who used ruxolitinib cream, 52.2% and 50.7% achieved NRS4 (proportion of patients whose itch severity decreased by at least 4 points on an 11-point (0-10) numerical rating scale), with itch reduction beginning 12 hours after first use of the drug.

Ruxolitinib cream has shown promising therapeutic effects by reducing the activity of JAK1 and JAK2 in atopic dermatitis, reducing itching, rash, and skin redness, thereby reducing or lessening the severity of signs and symptoms.

What are the side effects of ruxolitinib cream

Ruxolitinib cream is designed to deliver the drug directly to the affected skin and limit the potential for side effects from oral administration. The more common ones are nasal swelling, diarrhea, bronchitis, ear infections, increased eosinophil count, hives, folliculitis, tonsillitis and runny nose. The incidence of these adverse reactions is similar to the incidence of adverse reactions seen with placebo treatment in clinical trials.

Ruxolitinib cream is FDA-approved for short-term (8-week) use as part of an atopic dermatitis treatment regimen, or for intermittent use based on atopic dermatitis symptoms and affected skin areas.